Top 50 Medical VC Funds in Denmark

Investor	Medical Denmark investments
BioInnovation Institute	12
Novo Holdings	8
Vaekstfonden	6
Vaekstfonden	4
Sunstone Life Science Ventures	4
Seed Capital	3
Wellcome Trust	2
PSV	2
CAPNOVA	2
Industrifonden	2
People Ventures	2
Innovation Fund Denmark	2
Crowberry Capital	2
VentureFriends	2
European Investment Bank	1
BlueYard Capital	1
Teknoinvest	1
VF Venture	1
+ND Capital	1
V-Bio Ventures	1
BankInvest Biomedical Venture	1
Dansk Erhvervsinvestering	1
p53	1
Inovo VC	1
Roche Venture Fund	1
DigitalDx Ventures	1
GoBeyond	1
LSP BioVentures	1
SLS Venture	1
SEB Venture Capital	1
Polaris Partners	1
Forbion Capital Partners	1
Amino Collective	1
Bossanova Investimentos	1
VIB	1
Novo Ventures	1
Danske Bank	1
Innovestor	1
Sound Bioventures	1
LS Polaris Innovation Fund	1
Nucleus Capital	1
Crista Galli Ventures	1
SOSV	1
LF Investment	1
Seventure Partners	1
Sanofi Ventures	1
CBC Investment Group	1
Sofinnova Partners	1
EASME - EU Executive Agency for SMEs	1
M Ventures	1

BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.

Investment focus

Biotechnology, Medical, Health Care
Convertible Note, Pre-Seed, Debt Financing
Denmark, Germany, Switzerland

Portfolio highlights

NorFalk — NorFalk rethinks the way to produce surfactants: the active and stabilizing ingredients in household care and personal care consumer products.
TriptoBIO — TriptoBIO is developing a platform for producing natural plant compounds that will support the health of our planet. Our goal is to create a future where everyone can benefit from the power of plants, without depleting natural resources. Our first compound will liberate the world from rat poison
HHC Medical — HHC Medical is a health tech company developing targeted non-invasive drug delivery devices through electroporation to transfect a large number of cells. It was founded in 2019 and is headquartered in Hillerød, Denmark.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series A, Series B, Series C
United States, Denmark, United Kingdom

Portfolio highlights

ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
Myricx Bio — Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases.

Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.

Investment focus

Software, Information Technology, SaaS
Seed, Funding Round, Pre-Seed
Denmark, United States, United Kingdom

Portfolio highlights

Wedio — Buy & Rent professional film equipment from trusted creators near you. Buy & rent cameras, lenses, drones with Global Coverage. Explore
Keepit — The Keepit Cloud is the most cost-effective solution on the market with 20+ years of experience. Learn more about our next-level data protection services
kleen hub — Kleen hub is Denmark's first digital return system for reusable coffee cups and food packaging.

Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.

Investment focus

Software, SaaS, Information Technology
Seed, Funding Round, Pre-Seed
Denmark, United States, Norway

Portfolio highlights

Wedio — Buy & Rent professional film equipment from trusted creators near you. Buy & rent cameras, lenses, drones with Global Coverage. Explore
Keepit — The Keepit Cloud is the most cost-effective solution on the market with 20+ years of experience. Learn more about our next-level data protection services
kleen hub — Kleen hub is Denmark's first digital return system for reusable coffee cups and food packaging.

Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.

Investment focus

Biotechnology, Health Care, Medical
Funding Round, Series B, Series A
Denmark, Sweden, Switzerland

Portfolio highlights

Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.

Seed Capital invests in Danish tech businesses with global ambitions. We are focused on "late seed"-stage companies, typically investing 1-3 MEUR in rounds of 1-6 MEUR. Proud backers of Trustpilot, Vivino, Lunar, Templafy, Dixa, Forecast, and many other great companies.

Investment focus

Software, Health Care, SaaS
Seed, Funding Round, Series A
Denmark, United States, United Kingdom

Portfolio highlights

Flatpay — Flatpay's fair, flat-rate pricing simplifies payments & cuts costs. Benefit from our comprehensive solution & superior customer service. Join us now!
Mesh Bio — Mesh Bio is a digital health startup that is transforming chronic disease management through predictive analytics. Mesh Bio works with healthcare providers and stakeholders to provide innovative solutions that transform health screening and disease management. They translate clinical data and numbers into actionable insights that help patientsbetter manage their health, lifestyle and disease risks.
Embla — Embla provides an online medical weight loss treatment using prescription drugs and coaching. The company provides patients with evidence-based treatments, digital tools, medication, and coaching to facilitate sustainable weight loss. Embla was founded in 2021 and is headquartered in Copenhagen, Denmark.

Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Grant, Series C, Funding Round
United States, United Kingdom, Germany

Portfolio highlights

Vaxxas — Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.
DataDotOrg — data.org brings together philanthropy, technology, academia, and social impact organizations to build the field of data science for social impact.
Feinstein Institute for Medical Research — Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes ofbehavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

PreSeed Ventures are the preferred travel companion for trailblazing founders when they set out on the journey of transforming startup dreams to successful businesses. Founded in 2000 they have an exceptional track record of spotting, fostering and financing tomorrow’s winners in syndication with top-tier investors locally and globally. As the namesuggests, PreSeed Ventures operates at the earliest stages, where founders need the professional, operational & systematic support of a VC, but the risks are still too high for most VCs in seed stages. Yet to the powerhouse of experts behind PreSeed Ventures, who have experience from hundreds of startup journey in the pre-seed stage, it is an opportunity to support and nurture the growth of promising startups on the rise, minimizing the time and risk to the next investment round.PreSeed Ventures has grown out of the technological research environment at Denmark’s Technical University, DTU. In 2020 they launch their first full blown commercial venture fund, yet continuing to be a subsidiary company to the university.

Investment focus

Software, Information Technology, SaaS
Seed, Pre-Seed, Funding Round
Denmark, United States, United Kingdom

Portfolio highlights

spektr — Explore spektr's tailored compliance automation solutions for KYB monitoring, AML compliance, risk management, and more. Try our no-code, customizable platform for free today!
UltiHash — Data powers breakthroughs. UltiHash is the storage foundation to accelerate them: blazing fast, highly efficient, and built for sustainable long-term growth.
Yacheng Network — Yacheng Network is a provider of information technology and software services that specializes in offering these services.

They are an investment and development company providing capital, solid business experience and a strong network in order to turn innovative ideas into successful businesses. They cover all of Denmark from their offices in Aarhus, Roskilde, Copenhagen, Viborg and Kalundborg.

Investment focus

Software, Information Technology, Internet
Funding Round, Seed, Pre-Seed
Denmark, United States, India

Portfolio highlights

Ulobby — Ulobby is an automated tool for stakeholder management and political monitoring
Mechanic Miner — Mechanic Miner is a 2D construction/survival game with mechanical steam-powered machines. You are stranded on a strange and forbidding planet, where survival is made difficult by hostile animals and plant life. From your home world you did bring a multitool, which is able to craft any kind of machine part - provided the requisite rawmaterials can be found. Relying solely on the technology you brought, you set out to explore a whole world. You can progress through the game by acquiring new types of steam-powered technology elements, that are necessary to delve deeper into the diverse biomes of the planet, and perhaps, ultimately, discover the means to escape. You can construct any kind of machine of your own design - and any kind of machine can be simulated by the game's physics engine - and of course, designs can be shared with your friends.
ResoTher Pharma — ResoTher Pharma is a privately held biotechnology company located in Copenhagen, Denmark. The company is focused on developing peptide-based drugs derived from the endogenous immunomodulator Annexin 1A as resolution therapy for diseases where neutrophil-driven inflammation plays a key pathological role.

Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.

Investment focus

Software, Biotechnology, Information Technology
Funding Round, Series A, Seed
Sweden, United States, Denmark

Portfolio highlights

Arevo — Arevo offers liquid and granular amino acid fertilizer technologies for faster and better plant establishment.
Telness Tech — We help telcos maximize customer happiness and minimize OPEX through automation. Our proprietary, cloud-based, end-to-end BSS/OSS platform is connectivity ready in 64 countries.
ZeroPoint Technologies — ZeroPoint Technologies AB was created in 2016 as a spinout from Chalmers University of Technology. The Intellectual Property Portfolio related to computer memory management was the acquired from the University and transferred into a new startup.The Technology, ideas and many of the people behind and with ZeroPoint comes from Professor PerStenströms research group, which is internationally recognized for excellence within high-performance Computing. Since its creation, ZeroPoint has attracted skilled people from industry, finance and the startup community and raised its’ first round of Venture Capital in 2016.

People Ventures are your dreamcast team of co-founders, investors, executives, engineers, academics and industry experts. Together with talented entrepreneurs — We shape fantastic businesses through operational and commercial execution.

Investment focus

Health Care, Internet of Things, Software
Seed, Pre-Seed, Series A
Denmark, Sweden, United States

Portfolio highlights

Uniify — Uniify is a no-code customer onboarding software that makes it fast, easy and secure for financial companies to onboard their customers. Save your business time and money, and build onboarding flows for your customers in minutes instead of months.
proemial — Proemial is building an open platform that connects researchers to a larger and more diverse audience through personalized summaries of the latest research papers. The mission is to make it easy to read, discuss, understand and engage with recent discoveries, the researchers that produce them, and the companies that commercialize them.
Version Lens — Meet your new Product Management Co-Pilot. Reduce overhead for your product team so you can focus on what truly matters, building outstanding products.

Innovation Fund Denmark invests in the development of new knowledge and technology creating growth and employment in Denmark. The Fund focuses on societal challenges, strengthens research, and increases innovation commitment within private companies.The Fund provides risk capital that enables cutting-edge initiatives to achieve resultssubstantially impacting the Danish society. Innovation Fund Denmark is also responsible for the future societal partnerships, where companies, universities, and public authorities will work together on challenges facing the society today.

Investment focus

Software, SaaS, Information Technology
Grant, Pre-Seed, Seed
Denmark, United States

Portfolio highlights

Artelize — Discover events, performers and works within classical music, opera, musical, ballet & dance and drama. 174248 events, and 59606 artists and creators.
Tryp.com — There is always a reason to go! We use artificial intelligence to find the best travel deals at the lowest price. The algorithm compares and connects flights, trains, and buses to create the perfect multidestination trips with matching hotel offers.
Curvature AI — Grow your revenue with discounts and special offers selected and optimized by AI.

Crowberry Capital invests at seed and early stage in emerging technology ventures in the Nordics. Our mission is to back people that are good for companies and build companies that are good for people. We have a strong follow-through philosophy and commit to putting your company first.

Investment focus

Software, Information Technology, Gaming
Seed, Series A, Pre-Seed
Iceland, Denmark, Finland

Portfolio highlights

Saidot — Saidot is a governance tool for safe, ethical and transparent AI.
Social First — We create games that are social experiences, span decades and extend beyond gaming; giving our players platforms to create meaningful relationships with people all across the world.
Scaleup Finance — Improve your financial management

We are an early stage investor investing in Seed and Series A startups.

Investment focus

FinTech, E-Commerce, Software
Seed, Series A, Funding Round
Greece, United Kingdom, United States

Portfolio highlights

Cube AI — Cube AI boosts back-office logistics efficiency, allowing teams to handle more loads and focus on human relationships.
MoneyHash — MoneyHash provides access to payment and fintech services across the Middle East & Africa with one simple integration.
Harbor Lab — Designed to streamline the port cost management processes and optimize operational efficiency for cargo operations and husbandry services by leveraging technology and automation.

European Investment Bank (EIB) provides lending, borrowing, and treasury services primarily in the European Union.The company offers project loans for the public and private sectors; loans to banks and other intermediaries; structured finance products; guarantees and securitization instruments for senior and subordinated debts; project bonds;equity and fund investment products such as infrastructure equity and debt funds, and environmental funds; and venture capital funds and security packages for funds.The company also offers microfinance; risk sharing finance for research, development, and innovation projects; finance and technical expertise for sustainable energy projects; infrastructure project advisory services; support for urban development projects; guarantees for transport infrastructure; and funding for public-private partnerships and small- and medium-sized enterprises.EIB serves the transportation, global loans, energy, industry, health, education, water, sewerage, infrastructure, services, telecommunications, agriculture, and fisheries sectors.European Investment Bank was founded in 1958 and is based in Luxembourg.

Investment focus

Biotechnology, Health Care, Software
Debt Financing, Post-IPO Debt, Funding Round
France, Germany, Ireland

Portfolio highlights

In Ovo — We are on a mission to improve animal welfare in the poultry sector, and we have the technology to make it happen.
Battolyser Systems — Battolyser Systems aims to stimulate the development, production, and commercialization of battolyser technology and is looking for skilled and highly motivated people to join the team. The Company was founded in 2018 by dr. prof Fokko Mulder (Technical University of Delft) together with Kees Koolen (former CEO of Booking.com and former COO ofUber) and is led by CEO Mattijs Slee (previously Shell Hydrogen). The company has a unique patented technology that has the lowest production cost for green hydrogen in the market and does not require scarce materials.
Husk Power Systems — Hybrid Power Plant and Distribution Network Company

BlueYard backs founders building the interconnected elements that can become the fabric of our future.

Investment focus

Software, Cryptocurrency, Internet
Seed, Series A, Funding Round
United States, Germany, France

Portfolio highlights

Insempra — Origin.Bio creates synthetic microorganisms that can make many of the same ingredients as traditional chemical industrialization processes today, but with significantly fewer energy requirements and waste produced while eradicating the need for petrochemicals.The company drives the convergence of engineering with biology, using DNA as theprogramming language. Rather than editing genetic material only in or out of DNA, engineers can hack entirely new organisms that have never existed — all powered by computing, automation, and artificial intelligence (AI)/machine-learning while leveraging millions of years of evolution. Operating at an atomic level, the company farms organisms with microscopic precision and integrates them into existing original equipment manufacturer (OEM) manufacturing processes. This asset-light approach enables Origin.Bio to generate sustainable materials at speed in a cost-effective way, without compromising on performance.
ExpressionEdits — Redefining the status quo of protein expression
Transcripta Bio — Transcripta Bio is a company dedicated to drug discovery, with a focus on numerous diseases at once, at a never-before-seen pace and scale, with lesser risk and greater assurance.

Teknoinvest is a premier Scandinavian venture capital company. They invest in areas of emerging technologies within the ITC and Life Sciences sectors. Their main geographical scope is Scandinavia and the USA. Teknoinvest was established as the first venture capital investment company. Teknoinvest is one of the most successful VCÂ´s in Scandinaviaaccording to track record of value created for their investors.

Investment focus

Biotechnology, Health Care, Medical
Series B, Funding Round, Series A
Sweden, Norway, United States

Portfolio highlights

GLO — glō is a venture-backed company focused on the development and commercialization of advanced LED display products using nanotechnology. The unique nanotechnology is based on 11 years of research at Lund University’s Nanometer Structure Consortium. Headed by Professor Lars Samuelson, one of the world’s leading scientists in this field, who haspublished more than 500 papers related to this technology.glō's first office is in Lund, Sweden, where basic material research continues for the next generation nanotechnology. glō's research and product development along with pilot fabrication operation is carried out at glō-USA in Sunnyvale, California. In 2016, glō established an Asia office in Taipei, Taiwan, one of the largest and fastest-growing regions for LED lighting and display applications.glō's technology sidesteps the technical limitations of current planar LED technology. It allows for the creation of highly efficient, stable and ultimately unique red, green, blue (RGB) emitters out of one material system. It aims to achieve the industry’s best color stability and ultimately enables the growth of red, green and blue emitters on the same wafer. Highly-efficient white LEDs with high color rendering will be possible without the need for phosphor conversion. It is the next enabling technology for advanced display, illumination and automotive applications.glō nanowire light-emitting diodes (nLEDs) are based on its proprietary hetero-structured semiconductor nanowire epitaxial growth and process technologies for which standard manufacturing equipment and materials can be utilized.glō currently holds over 175 patents across US, Europe and Asia. These patents are not subject to any cross-licensing with the LED oligopoly. The glō team is constantly strengthening its intellectual property position in this technology and related applications.
SantoSolve — SantoSolve is developing topical analgesic products based on non-radioactive strontium as the active substance. The Development program was initiated based on experimental clinical use of strontium-based products showing evidence of strong local analgesic effects on several localized pain conditions of both nociceptive and neuropatic origin. Nosignificant adverse effects associated with the treatment was reported.The companyâ€™s lead product, 2PX, is topically administered, utilizing dermal penetration enhancers for delivery of the active agent to its subdermal site of action. Phase I safety and pharmacology studies showed the active agent to have low systemic bioavailability, and only few and minor adverse effects were observed at the site of administration. In open label Phase II clinical trials, the product has shown strong analgesic effect in both nociceptive and neuropatic pain conditions. In follow up, placebo controlled trials, the analgesic effect of the product has been further documented. In the companyâ€™s most advanced pain indication under study, osteoarthritis, the company has recently completed the Phase II program.These trials supports the open label results and document statistically that the analgesic effect in patients treated with 2PX is superior to that observed with placebo treatment.
Sol Voltaics — Founded in 2007, Sol Voltaics AB is a venture-backed, development-stage nanotechnology company focused on development and commercialization of highly efficient, third-generation photovoltaic concentrator solar cells based on its proprietary heterostructured nanowire epitaxial growth and process technologies.

Vaekstfonden makes equity investments in Danish companies with a track record as well as in young entrepreneurial, innovative enterprises with an ambition for global growth.

Investment focus

Software, Biotechnology, SaaS
Seed, Funding Round, Series A
Denmark, United Kingdom, Iceland

Portfolio highlights

Performativ — Performativ develops modern solutions for the asset and wealth management industry. Our clients span from small investment advisors to enterprise banks.
Chromologics — Chromologics produce natural sustainable colors. Our flagship product is ChromoRed which performs better than existing natural, red colorants. ChromoRed is also applicable with vegan, kosher and halal diets.
Onomondo — Onomondo is a global IoT network. Our IoT SIM and cloud platform future proof your devices with full data transparency, freedom to leave, and no third parties.

+ND Capital (NanoDimension) is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series C, Series A
United States, Switzerland, Denmark

Portfolio highlights

Vandria — At the vanguard of Mitochondrial research
Partillion Bioscience — Unlock your research today with the word's first functional single-cell biology reagent platform. Next generation assay kits for single-cell secretion analysis and more.
PulseSight Therapeutics — PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness.

V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biotech, pharmaceutical and agriculturalsectors.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Seed
Belgium, France, United Kingdom

Portfolio highlights

Flindr Therapeutics — Immagene develops personalized cancer immunotherapies to fight multiple cancer type.
Protealis — Sustainable plant proteins for Europe
Augustine Therapeutics — Augustine, Innovative therapies for neuromuscular and neurodegenerative diseases

BankInvest Biomedical Venture makes investments in research-based biotechnology companies in Europe.

Investment focus

Biotechnology, Health Care, Medical
Funding Round, Series B, Series C
Denmark, United Kingdom, France

Portfolio highlights

F2G — F2G is a biopharmaceutical company developing novel therapies for life-threatening fungal infections.
Nereus Pharmaceuticals — Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent forthe treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.
Resistentia Pharmaceuticals — Resistentia Pharmaceuticals, a biopharmaceutical company, develops immunotherapeutic products for allergic asthma and inflammatory disorders. It provides Immunoglobulin E for allergic reactions, including asthma, rhinitis, and dermatitis; and C5a for the treatment of inflammatory conditions, such as rheumatoid arthritis, asthma, and multiplesclerosis. Resistentia Pharmaceuticals AB was founded in 1998 and is based in Uppsala, Sweden.

Dansk Erhvervsinvestering is a company that assists individuals with investing.

Investment focus

Medical, Health Care, Biotechnology
Funding Round
Denmark

Portfolio highlights

Genmab — Genmab is an international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's discovery, development, and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Its primary goal is to improve the lives ofpatients who are in urgent need of new treatment options.
PremiTech — PremiTech A/S develops systems management software. It offers Performance Guard, a solution that enables IT departments to get real-time measurement of end-user application and infrastructure IT performance in software as a service model. The company also provides Performance Guard CIO Dashboard Module, which provides a view into the ITinfrastructures performance based on grouping by location and application; and Performance Guard Health Check Module that delivers reports on infrastructure components, including applications, mid-tier servers, network and PC Infrastructure for automated, out-of-the-box fast performance documentation, and issue resolution. In addition, it offers monitoring and documentation, and performance monitoring solutions. The company has strategic partnerships with HP, Computer Associates, BMC, VMWare, IBM, and Microsoft. PremiTech A/S was founded in 1999 and is headquartered in Hedehusene, Denmark. As of 2008, PremiTech A/S operates as a subsidiary of CapaSystems A/S.

p53 identifies and invests in innovative healthcare companies, particularly in the fields of biotechnology and medical devices.

Investment focus

Biotechnology, Medical, Life Science
Series A
Norway, Denmark

Portfolio highlights

Calluna Pharma — Join Calluna Pharma on our mission to revolutionize the treatment of inflammatory and fibrotic diseases. With a robust pipeline, seasoned leadership, and strategic alliances, help us reshape the treatment landscape for the better.
Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.

VC for the most ambitious founders in CEE

Investment focus

Software, B2B, Apps
Seed, Pre-Seed, Series A
Poland, United States, Italy

Portfolio highlights

Pythagora — Dev tool that uses AI to generate integration tests by analysing server activity without the developer having to write a single line of code
Smartschool — Get your 1400+ SAT score faster with AI
Quantia — Unlock ecommerce potential with Quantia's solutions. Solve critical challenges with our AI data analytics platform.

The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent ofcollaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, United Kingdom, Spain

Portfolio highlights

DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team News See more Our Work OUR APPROACH ABOUT DIABETES
Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas

DigitalDx Ventures is a Silicon Valley Venture firm uniquely positioned to find, support, mentor and grow the outliers in digital healthcare. DDX invests in early stage companies who effectively and efficiently harness the power of artificial intelligence and big data to profoundly impact outcomes in both diagnostics and therapeutics.

Investment focus

Biotechnology, Health Care, Medical
Series A, Seed, Funding Round
United States, Canada, Denmark

Portfolio highlights

Nephrosant — NephroSant is a fast-paced diagnostic startup founded by physicians, with a team of world-class scientists, engineers and clinicians, focused on applying the founding team's years of clinical research expertise to improve global kidney health.
GLX Analytix — GLX Analytix is a biomedical company that develops a new technology to identify a biomarker. The company was founded in 2019 and is based in Copenhagen, Denmark.
Optina Diagnostics — Optina Diagnostics is a leader in the early detection of Alzheimer's disease and develops its solutions using Artificial Intelligence.

GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.

Investment focus

Information Technology, Medical, Software
Funding Round, Seed, Series A
Switzerland, Germany, United Kingdom

Portfolio highlights

LEND — LEND provides peer to peer lending in Switzerland. It connects investors with borrowers. Moreover, investors earn substantial returns and borrowers benefit from low interest rates. The company is based in Switzerland and it was founded in 2015.
AVAtronics — AVA Active Noise Cancellation (ANC) Solution is a breakthrough in Audio Industry. AVA is the first and only TRUE WIDE-BAND ANC in the market capable of selectively cancelling all annoying noises we want to get rid of without compromising the quality of Music or speech.
Blumer — Blumer is a social networking platform that provides social networks that can monetize time by consuming advertisements, selling nfts, and making crypto transactions. It offers social networks, crypto, digital marketing, and blockchain.

LSP BioVentures is a venture capital fund focused on opportunities in the life science arena. Based in Cambridge (MA) in the USA; the fundâ€™s management combines the strength of its parent company, Life Sciences Partners Venture Capital firm in Europe and a dedicated team of experts in the USA.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Germany, United Kingdom

Portfolio highlights

Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
Muna Therapeutics — Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.
HotSpot Therapeutics — HotSpot Therapeutics is a biotech startup that focuses on the development of allosteric therapies targeting regulatory sites on proteins. It develops a therapy platform to discover medicines and provide proper treatment to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspotstructures, harnessing the power of data science in its multidisciplinary approach to drug discovery, and helps patients to get treatment against several diseases.HotSpot Therapeutics was founded in 2017 and is headquartered in Boston, Massachusetts.

SLS Venture, a Scandinavian-based venture capital company, is the result of the merger of the life science team from The Sixth Swedish National Pension Fund, Medicon Valley Capital and Innoventus. The fund is one of the largest investment funds in Scandinavia in the life science sector with approx. â‚¬ 270 M (USD 325 M) under management.

Investment focus

Health Care, Biotechnology, Medical
Series C, Funding Round, Series A
Denmark, United States, Sweden

Portfolio highlights

AdvanDx — I found a great domain name for sale on Dan.com. Check it out!
OxThera — OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera’s intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria, and enzymes. Oxabact® holds Orphan Drug designations in Europe and in the US for thetreatment of primary hyperoxaluria.
Action Pharma — Action Pharma A/S operates as a research and development focused biotechnology company. It discovers and develops new drugs and treatment concepts to treat cardiovascular disease and inflammatory diseases, as well as metabolic diseases, such as type-II diabetes and obesity. The company's product pipeline includes AP214, a modifiedÃMSH-peptide analogue for the treatment of post-surgical kidney injury associated with cardiac surgery; and AP1030 and AP11 series, oral anti-diabetic (OAD) for the treatment of type-II diabetes associated with overweight/obesity. Its product pipeline also comprise AP1189, an oral anti-inflammatory compound for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and AP405, a modified MSH peptide analogue for the treatment of inflammatory skin diseases, such as atopic dermatitis. The company was founded in 2000 and is based in Holte, Denmark.

SEB Venture Capital is a Fintech investor that helps entrepreneurs and innovators launch and grow profitable businesses. They primarily serve as a strategic corporate venture focused on Fintech investments, with the option of partnering with SEB. They are also on the hunt for game-changing inventive solutions to new technologies that will make thefinancial industry smarter, safer, and more environmentally responsible, as well as more user-friendly. They also function as an evergreen fund, giving them the flexibility and staying strength to focus on long-term wealth development depending on what is best for the firm and its shareholders.

Investment focus

Software, Information Technology, Financial Services
Funding Round, Series A, Series B
Sweden, Denmark, United Kingdom

Portfolio highlights

Airsonett — Research-based medical technology company which leads the way in the development of non-pharmaceutical treatment for allergic asthma.
EnginZyme — EnginZyme is a biotechnology company that specializes in biocatalysis. It creates products for easy and cost-efficient implementation of biocatalytic processes and helps the chemical industry transition to a sustainable way of operating.The company is driven by a mission to make biocatalysis the first choice for chemical process designersworldwide.
Qvantum — Qvantum is driven by a passion for a sustainable future and we are changing the way the cities of Europe are heated.

Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics,and genomics.

Investment focus

Health Care, Biotechnology, Medical
Series B, Series A, Series C
United States, Ireland, Singapore

Portfolio highlights

Nomad Health — Search travel nurse jobs nationwide. Earn more money, haggle-free. Receive expert support without the pushy tactics of a traditional recruiter.
Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.
Tectonic Therapeutic — Tectonic and AVROBIO have completed their anticipated merger.Please follow this link to our press release for additional information.

Impacting the future of medicine.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, United Kingdom, The Netherlands

Portfolio highlights

Pheon Therapeutics — Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.The company was founded in 2022 and is based in London,England.
Bicycle Therapeutics — Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need.The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Progentos Therapeutics — Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.

Amino Collective is an institutional venture capital firm investing at seed stage in health and bio companies. They help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, lifescience, and synthetic biology.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Pre-Seed
United States, Germany, United Kingdom

Portfolio highlights

Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
ExpressionEdits — Redefining the status quo of protein expression
Tandem Health — Focus on providing care, while Tandem helps you easily write medical notes directly after the patient consultation.

BossaNova is the number one Brazilian Micro Venture Capital. We are the most active investor in the pre-seed stage in Latin America with more than 1200 investments in over 1000 Startups. We also invest in global companies, directly or through co-investment syndicates on AngelList.

Investment focus

Software, Information Technology, Financial Services
Seed, Pre-Seed, Funding Round
Brazil, United States, Mexico

Portfolio highlights

SenseUp — SenseUp provides IoT, big data, machine learning, and computer vision for the real-time needs of the financial market. It improves the way organizations interact with data by using microintegrations to orchestrate different data sources, consumers, and data flows in support of processes and decision-making.
HubLocal — HubLocal is a platform that attracts more customers to companies, making them automatically found on all Internet maps.
Hiperbanco — O Hiperbanco é uma Fintech que oferece diversos serviços financeiros, com destaque para o produto “Banco Digital Whitelabel”. Seu público-alvo abrange empresas de diversos setores, que buscam soluções financeiras flexíveis e personalizadas com sua marca, como Conta, PIX, TED, Boleto, Recargas, Cartão, Emprestimos, dentre outros. Os principaisdiferenciais do Hiperbanco incluem sua abordagem centralizada no cliente, desenhando juntos um produto financeiro único e atuando com tecnologias de ponta.

Strategic research in on life sciences and biotechnology

Investment focus

Biotechnology, Pharmaceutical, Health Care
Series A, Series B, Funding Round
Belgium, Brazil, Denmark

Portfolio highlights

Protealis — Sustainable plant proteins for Europe
Muna Therapeutics — Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.
Augustine Therapeutics — Augustine, Innovative therapies for neuromuscular and neurodegenerative diseases

Novo A/S is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, and the holding company of the Novo Group and as such the majority shareholder in the publicly listed companies Novo Nordisk A/S and Novozymes A/S.Novo A/S was established in 1999 prior to the demerger of Novo NordiskA/S, where Novozymes A/S was established as a stand-alone publicly listed company. Novo's purpose and objectives are to manage the Foundation's financial assets and to ensure the Foundation sufficient dividends to cover its grant obligations for medical and scientific research etc. in Scandinavia.Novo A/S attains these objectives through:compliance with the rules and principles which are set out in the Articles of Association of the Novo Nordisk Foundation regarding exercise of the voting rights of A and B shares in Novo Nordisk A/S and Novozymes A/S, respectively, assurance that all companies in which the company has a material influence actively contribute to the development of the Novo Group and operate their business in accordance with the visions and values of the Novo Group, maintenance of a material influence on Novo Nordisk A/S and Novozymes A/S, and investment and financing business including placing of capital in companies and real property domestically and abroad.Novoâ€™s overall investment strategy is thus to maintain ownership of Novo Nordiskâ€™ and Novozymesâ€™ shares at a level just above 25% and to invest dividends from these companies and other income in the life science area as well as in a broad portfolio of financial assets.Novo A/S has since 1999 established itself as an international venture capital partner in the life science area and has invested in over 50 companies in Denmark, Europe and North America. Through its financial investment activities Novo A/S seeks to spread the companyâ€™s total financial risk and at the same time to ensure a high return taking into consideration the chosen risk profile. In 2007 Novo A/S together with the Novo Nordisk Foundation established â€˜Novo Seedsâ€™. The new program (split into two sub-programs) is aimed at supporting early stage applied research in the life science area in Scandinavia. At the beginning of 2009 Novo A/S launched a new initiative, investing 'growth equity' into promising later stage/commercial stage life science companies. Novo A/S represents the interests of the Novo Nordisk Foundation through participation on the boards of the companies in the Novo Group.The companies in the Novo Group are members of a 'family of companies', independently managed, but sharing a set of common values as set out in the 'Charter for Companies in the Novo Group'. In the Charter these core values, commitments and management principles that companies in the Novo Group should live up to are described.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, United Kingdom, Switzerland

Portfolio highlights

INBRACE — Swift Health Systems is a stealth stage medical device company developing INBRACE: a revolutionary, easy to use, wide indication, personalized orthodontic system hidden behind the teeth. Our patented self-guiding technology uses light and continuous forces to gently correct your smile with less pain and fewer doctor visits. INBRACE is FDAregistered and a catalyst for disruption in orthodontics. INBRACE increases the number of people who will seek orthodontic treatment by addressing the top concerns for patients while driving practice growth for clinicians. Our platform leverages digital treatment planning, computer modeling, and direct digital manufacturing to create a scalable, patient customized solution that delivers the standard of care across the entire range of orthodontic cases.
Theraxyte — Theraxyte is an innovative nano-drug developer. It focuses on the R&D and application of new nano-drugs, especially innovative drugs.
Amolyt Pharma — We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.

Danske Bank is a Nordic universal bank offering a full range of banking services. It was founded 5 October 1871 as Den Danske Landmandsbank, Hypothek- og Vexelbank i Kjøbenhavn (The Danish Farmers' Bank, Mortgage and Exchange Bank of Copenhagen). It is headquartered in Copenhagen, Denmark and is one of the major retail banks in the northernEuropean region with over 5 million retail customers.Danske Bank was number 454 on the Fortune Global 500 list for 2011.

Investment focus

Biotechnology, Apps, Payments
Funding Round, Post-IPO Debt, Debt Financing
Denmark, Sweden, United States

Portfolio highlights

FlexQube — FlexQube is a manufacturer and distributor of material handling equipment. They offer a flexible system of a few standard components that can be used to build industrial material handling applications. Their products are pallet carts, kit carts, and shelf carts.
Rottneros — Rottneros manufactures paper pulp products. They offer mechanical pulp as well as bleached and unbleached chemical pulp. They also offer baking paper, wallpaper, packaging, air filters, electrical applications, datasheets, and laminate floors.
Renewable Power Capital — Renewable Power Capital invest in the development, construction and long-term ownership of solar, onshore wind and battery storage projects.

Welcome to Innovestor! We are a Finnish investment company focusing on venture capital, corporate venturing services, and real estate.

Investment focus

Software, Health Care, Manufacturing
Seed, Funding Round, Series A
Finland, Denmark, Sweden

Portfolio highlights

Capalo AI — We maximize the value of your energy storage systems. Now and in the future.
Kausal — Kausal helps cities turn their climate goals into action through a digital platform that enables smarter collaboration around key data.
Confidentialmind — The ConfidentialMind software stack enables you to integrate AI-solutions such as language models into your workflows and processes without data leaks to third parties. We will find a way to protect your data.

Sound Bioventures is a venture capital fund investing in clinical stage companies.

Investment focus

Medical, Biotechnology, Therapeutics
Series A, Seed, Series B
France, Denmark, United States

Portfolio highlights

VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
AbolerIS Pharma — AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance.

The LS Polaris Innovation Fund aims to accelerate the commercial and therapeutic potential of early stage academic research.

Investment focus

Biotechnology, Medical, Biopharma
Series A, Series B, Funding Round
United States, Denmark

Portfolio highlights

Glympse Bio — Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases. The company’s technology uses precisely engineered diagnostic agents that interrogate the body for certain disease states, and then carry the message to the urine for analysis. Glympse Bio’s platformtechnology was originally developed at MIT, and is founded by a team of world-renowned experts in nanomedicine and biomedical engineering.
Satellite Bio — Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It focuses on the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases.
Muna Therapeutics — Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.

Supporting purpose-driven founders solving systemic challenges to planetary health.

Investment focus

Biotechnology, Information Technology, Food and Beverage
Pre-Seed, Seed, Series A
Germany, United Kingdom, United States

Portfolio highlights

Planet A Foods — The chocolate revolution is here. 100% cocoa-free and unbelievably delicious. We call it QOA. You need to try it!
Trilobio — Fully automated biology for everyone
Izote Biosciences — Biomanufacturing Scale-Up Solution

Crista Galli Ventures invests in ambitious European healthtech companies at Seed and Series A. Our deep medical expertise, powerful network and agile approach enable founders to build important, world-class healthcare businesses.

Investment focus

Health Care, Wellness, Medical
Seed, Pre-Seed, Series A
United Kingdom, United States, Sweden

Portfolio highlights

Jude — Hey, we're Jude. A healthcare start-up on a mission is to bring bladder care into the mainstream.
Vitrue Health — At Vitrue Health, our mission is to reduce or eliminate the impact that musculoskeletal health issues have on over 40% of the population using cutting edge technology. We believe that the foundation of successful outcomes in musculoskeletal health, at every stage of the pathway, is accurate assessment. Whether it's a desk worker with early stages of neck pain or a patient having a total knee replacement, Vitrue's technology can help.
Collective Minds Radiology — Collective Minds® is the new radiology workspace. A cloud-based service for collaboration, consultation and access to new digital tools and expertise. We are building the largest global network of collective and artificial intelligence, with humans and machines.

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
NovoNutrients — NovoNutrients is working to turn waste CO2 into high-value, low-cost proteins and additives for food and feed by developing proprietary microbes and advanced gas fermentation systems.
Sodex Innovations — Sodex Innovations is a company which is specialized in developing assistance-systems and automating-kits for excavators

LF Investment is the investment arm of The Lauritzen Foundation, which is the parent company of the shipping companies J. Lauritzen (wholly-owned) and DFDS (42,8% holding). LF Investment has holdings in companies in the oil analysis, measuring equipment, software, biotechnology, and real estate sectors.

Investment focus

Medical, Wellness, Health Care
Funding Round
Denmark

Portfolio highlights

Minervax — We are MinervaX. A clinical stage biotech company focused on making a global impact by developing state-of-the-art vaccines.

Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.

Investment focus

Biotechnology, Health Care, Software
Series A, Funding Round, Series B
France, United States, Germany

Portfolio highlights

Sinay — Use the full potential of your data with intelligent solutions. Become more efficient on a daily basis and reduce your environmental impact.
Allozymes — Allozymes applies its proprietary platform technology to rapidly develop novel enzymes, revolutionizing the way that industries manufacture complex natural
Vedanta Biosciences — Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Sanofi Ventures invests in top tier biotherapeutic and digital health entrepreneurs who focus on helping patients and transforming the healthcare system.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, United Kingdom, Israel

Portfolio highlights

Q32 Bio — Q32 Bio is developing drugs targeting powerful regulators of both the innate and adaptive immune systems with the goal of re-balancing the immune system.
Atropos Health — Atropos Health rapidly provides personalized real-world evidence for any clinical decision
NextPoint Therapeutics — NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells.

CBC Investment Group started in 2009 in the midst of the financial crisis. The banks were on their knees, start-ups of small and medium-sized companies - all of a sudden they saw their credit and credit promises turned into demands for quick repayment and empty words. Serious talented entrepreneurs' ideas and companies risked going completelyunnecessary. In response to this crisis, they started the CBC Investment Group.

Investment focus

Biotechnology, Software, SaaS
Funding Round, Seed, Series B
Sweden, Denmark, Germany

Portfolio highlights

GLX Analytix — GLX Analytix is a biomedical company that develops a new technology to identify a biomarker. The company was founded in 2019 and is based in Copenhagen, Denmark.
Swiftly — World's first AI that applies for jobs. Say goodbye to creating CV's, searching and applying for jobs. Let Swiftly do it for you! Welcome to the new age.
Hugel Control — HUGEL, Inc. strives to be a global company that continuously creates innovative products, promotes universal health, and improves the quality of life through state-of-the-art technology and creativity.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

deepc — The Radiology AI Platform - Your effortless access to AI
Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
Micropep Technologies — Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact.The company currently works on four development programs: germination, flowering, growth, and weed control.

Executive Agency for SMEs

Investment focus

Biotechnology, Health Care, Software
Grant, Seed, Funding Round
Spain, United Kingdom, Switzerland

Portfolio highlights

AGADE — Esoscheletri Agade | Il primo esoscheletro intelligente per lavoratori progettato per ridurre il rischio di disturbi muscolari delle spalle nella movimentazione manuale dei carichi.
BroadBit Batteries — BroadBit is a technology company developing revolutionary new batteries using novel sodium-based chemistries to power the future green economy.
Aenitis Technologies — We develop innovative devices for cells therapy processing using Acoustic Radiation Forces.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Switzerland, United Kingdom

Portfolio highlights

LabGenius — Finding the next generation of drugs with machine learning, synthetic biology and laboratory automation
Outrun TX — Outrun TX develops a platform for the identification of therapeutics that selectively target the protein degradation pathway.
Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.